<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eduard Vieta, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francesc Colom, PhD, PsyD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H276260726">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adherence to pharmacotherapy is often poor in chronic medical illnesses, including bipolar disorder [
         <a href="#rid1">
          1-3
         </a>
         ]. Poor adherence is usually addressed during maintenance-phase treatment when patients are euthymic and stable.
        </p>
        <p>
         This topic reviews management of poor adherence to medications in bipolar disorder. Selecting a treatment regimen for maintenance treatment of bipolar disorder and the adjunctive psychotherapies that are used for maintenance treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H125037">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="headingAnchor" id="H125101">
         <span class="h2">
          Bipolar disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is a mood disorder that is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H125207">
         <span class="h2">
          Medication adherence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adherence to pharmacotherapy encompasses taking medication as prescribed with regard to dose, frequency, and timing [
         <a href="#rid5">
          5
         </a>
         ]. Adherence can be quantified on a continuum as a percentage of doses taken as prescribed during a specific interval, or expressed categorically as good, partial, and poor adherence [
         <a href="#rid6">
          6
         </a>
         ]. It is not known what level of adherence is required for good outcomes such as avoiding relapse. Common but arbitrary cutoffs for good adherence are taking at least 70 or 80 percent of prescribed doses [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Adherence within patients can change over time and vary between different drugs [
         <a href="#rid8">
          8
         </a>
         ]. As an example, a prospective observational study of patients with bipolar disorder (n = 88) found that adherence was worse with psychotropic medications than medications prescribed for general medical illnesses [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H124960">
         <span class="h1">
          EPIDEMIOLOGY OF NONADHERENCE
         </span>
        </p>
        <p class="headingAnchor" id="H112073">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many studies have found that poor adherence with pharmacotherapy occurs in roughly 50 percent of bipolar patients [
         <a href="#rid8">
          8,10-21
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective registry study (n &gt;44,000 bipolar patients prescribed
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or anticonvulsants) found that poor adherence occurred in about 46 percent, and that the median duration of adherence was 270 days [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study of patients (n = 275) in maintenance treatment who were followed for up to three years found that nonadherence occurred in 50 percent [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, a wide range of values for poor adherence in bipolar disorder have been reported; prevalence rates vary from 7 to 65 percent [
         <a href="#rid7">
          7,24,25
         </a>
         ].
        </p>
        <p>
         Studies of adherence in bipolar disorder include retrospective analyses of relatively large registries and administrative claims databases, as well as prospective or retrospective studies of clinical samples that are generally smaller. Different objective and subjective methods have been used to quantify adherence, such as counting pills; measuring serum drug concentrations; pharmacy refill records; electronic monitoring of pill bottle caps that record the opening of the bottle; electronic monitoring of blister pill packs; and reports from patients, clinicians, and family members [
         <a href="#rid6">
          6,7,26
         </a>
         ]. Studies also differ in their definition of adherence, the clinical status (euthymic, depressed, or manic/hypomanic) of patients when they were assessed for adherence, and length of follow-up, as well as the patients’ course of illness (eg, lifetime number of mood episodes) at the time of assessment.
        </p>
        <p class="headingAnchor" id="H519214169">
         <span class="h3">
          Long-acting injectable antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although long-acting injectable antipsychotics (eg,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ) are considered an option for nonadherent patients [
         <a href="#rid7">
          7,27
         </a>
         ], these drugs do not necessarily improve adherence. In a retrospective study of bipolar patients (n = 221) who received long-acting injectable second generation antipsychotics, nonadherence occurred in 47 percent; in patients (n = 413) treated with long-acting injectable first-generation antipsychotics, nonadherence occurred in 48 percent [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H125571">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many potential risk factors for poor medication adherence that may act individually or in concert [
         <a href="#rid7">
          7,28
         </a>
         ]. In addition, the reasons for poor adherence may change over time. Factors that are associated with nonadherence across multiple studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbid substance use disorders
         </strong>
         – This factor appears to be associated with poor adherence more than any other factor [
         <a href="#rid7">
          7,10,18,20,29-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Poor adherence is associated with adverse effects (eg, cognitive dysfunction, extrapyramidal symptoms, sedation, sexual dysfunction, and weight gain) as well as fear of side effects (eg, the medications are addictive) [
         <a href="#rid7">
          7,12,14,20,23,26,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient insight and beliefs
         </strong>
         – Adherence is worse among bipolar patients who [
         <a href="#rid7">
          7,12,13,17,23,36-39
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Deny that they are ill
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Believe the illness is not severe
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Have negative attitudes toward medications (eg, “Drugs are useless,” “I’m tired of taking medications,” or “They remind me that I’m sick”)
        </p>
        <p>
        </p>
        <p>
         Poor adherence is also associated with polypharmacy [
         <a href="#rid7">
          7,20,40
         </a>
         ]; difficulty with medication routines [
         <a href="#rid39">
          39,41
         </a>
         ]; cognitive impairment [
         <a href="#rid7">
          7,42
         </a>
         ]; comorbid personality disorders [
         <a href="#rid7">
          7,14,43
         </a>
         ]; impulsivity [
         <a href="#rid44">
          44
         </a>
         ]; more severe symptoms of bipolar disorder [
         <a href="#rid7">
          7,36
         </a>
         ]; younger age (eg, &lt;40 years) [
         <a href="#rid7">
          7,10,22,31,36
         </a>
         ]; nonwhite race [
         <a href="#rid7">
          7,31
         </a>
         ]; never married, separated, or divorced marital status [
         <a href="#rid7">
          7,31,32
         </a>
         ]; and homelessness [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H346062195">
         <span class="h2">
          Consequences
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon multiple retrospective analyses of administrative claims databases with thousands of bipolar patients, nonadherence is associated with [
         <a href="#rid11">
          11,45-47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emergency department visits (both all cause and for psychiatric diagnoses)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hospitalizations (both all cause and for psychiatric diagnoses)
        </p>
        <p>
        </p>
        <p>
         Studies of clinical samples also suggest that nonadherence may lead to recurrent mood episodes [
         <a href="#rid7">
          7,32,36,48
         </a>
         ] as well as more suicide attempts [
         <a href="#rid7">
          7,36
         </a>
         ] and hospitalizations [
         <a href="#rid7">
          7,14,19,31,36
         </a>
         ].
        </p>
        <p>
         Beyond the direct costs of hospitalizations [
         <a href="#rid31">
          31
         </a>
         ], nonadherence is associated with increased indirect costs due to absenteeism, disability, and worker’s compensation [
         <a href="#rid24">
          24
         </a>
         ]. In addition, noncompliance that is not recognized by clinicians can leave them with the false impression that patients are treatment-resistant, which may lead to unnecessary dose increases, medication switches, or adjunctive medications [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         In general medical patients, good adherence to drug therapy, compared with poor adherence, is associated with lower mortality [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H276260926">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H125281">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonadherence takes many forms, and it is important to distinguish patients who decline pharmacotherapy from patients who are willing to take their medications but do not do so for reasons such as forgetting, misunderstanding instructions, or misinformation about pharmacotherapy (eg, “I don’t want to get addicted”) [
         <a href="#rid26">
          26
         </a>
         ]. The reasons for nonadherence influence the interventions that are selected to improve adherence.
        </p>
        <p>
         It is worthwhile determining how patients understand their illness (eg, asking “What do you think causes bipolar disorder?”, “How does it affect you?”, and “Can it be controlled?”), and exploring patients’ attitudes and expectations of treatment [
         <a href="#rid50">
          50
         </a>
         ]. Irrational or erroneous beliefs about medications, negative attitudes towards pharmacotherapy, and the desire to manage the illness without medication can all interfere with adherence. In addition, it is helpful to know whether patients think they are at risk for recurrences and if so, what are the consequences. Patients who understand the personal consequences of recurrences may better absorb general information about the risk of recurrence.
        </p>
        <p>
         Three prerequisites for patient adherence to pharmacotherapy are that the regimen should be [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acceptable – Patients are more likely to accept pharmacotherapy if they can acknowledge their illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Understandable – Does the patient understand the rationale for the drug regimen? As an example, euthymic patients may not realize the need for maintenance therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Manageable – Practical issues often affect adherence.
        </p>
        <p>
        </p>
        <p>
         Patients who are prescribed maintenance pharmacotherapy are likely to be nonadherent at some point. Clinicians should adopt a long-term perspective and try to use episodes of nonadherence as a learning tool for patients [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         To promote adherence to treatment at the onset of therapy, patients starting pharmacotherapy should be told the following [
         <a href="#rid7">
          7,50-56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Take the medication as prescribed rather than on an as-needed basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There may be a lag of at least one week before a discernible response is apparent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects frequently occur during the first few days, but typically resolve within a week of starting the medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a dose is missed, the next scheduled dose should not be doubled.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If medication is effective, it is important to continue treatment for several (eg, six) months, even if symptoms remit sooner, to prevent relapse. (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Maintenance of medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Call to discuss side effects or other concerns or questions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Talk with the prescribing clinician before stopping medications.
        </p>
        <p>
        </p>
        <p>
         Techniques that can improve medication adherence include the following [
         <a href="#rid7">
          7,50-56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help patients accept the diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ask about prior use of pharmacotherapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discuss with patients their expectations of benefits and adverse effects
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elicit and emphasize benefits that are important to the patient
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Negative expectations about the effects of medications can diminish therapeutic efficacy and amplify unwanted side effects (see
         <a class="local">
          'Negative expectations'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discuss plans for dose titrations and how the clinician will monitor the use and benefit of medications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide simple and clear written instructions for taking prescribed medications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suggest pill boxes to organize daily doses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suggest the use of cues (eg, smartphone alarms, a written record, or pairing pill taking with another regular activity such as eating breakfast) as a reminder to take medications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ask about the patient’s ability to follow the regimen and address barriers to adherence
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discuss the need to maintain pharmacotherapy despite feeling better
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Praise desirable behavior and results
        </p>
        <p>
        </p>
        <p>
         Knowledge about bipolar disorder may also aid adherence. As an example, patients who become depressed after starting a medication may incorrectly attribute the depressive syndrome to the drug, rather than the course of illness. In addition, pharmacotherapy may preserve or increase cortical gray matter, white matter integrity, and hippocampal volume. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H122826749">
         <span class="h3">
          Therapeutic alliance
         </span>
         <span class="headingEndMark">
          —
         </span>
         It may be possible to enhance adherence by developing a therapeutic alliance (relationship) with patients and encouraging them to actively participate in treatment as partners [
         <a href="#rid7">
          7,36,57
         </a>
         ]. A prospective study of bipolar patients (n &gt;3000) followed for up to one year found that positive perceptions of collaboration with and empathy from psychiatrists was associated with better medication adherence [
         <a href="#rid58">
          58
         </a>
         ]. In addition, a study of depressed patients reported a high rate of medication adherence (85 percent) that was attributed to alliance building, which involved providing information about the illness and treatment, and approaching treatment as an experiment in which clinicians, patients, and family members were co-investigators [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         One model of the therapeutic alliance hypothesizes that the quality of the therapeutic relationship is better when clinicians and patients [
         <a href="#rid59">
          59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agree on the goals of treatment – Few patients pursue treatment with the goal of obtaining medications [
         <a href="#rid50">
          50
         </a>
         ]. Rather, they want relief (eg, to sleep better or return to work).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agree on the tasks to be completed to achieve the goals – It is helpful for patients to understand that adherence is not about control and obedience [
         <a href="#rid26">
          26
         </a>
         ]. Rather, adherence is a means for patients to reach their goals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Develop a bond (like and trust one another).
        </p>
        <p>
        </p>
        <p>
         Suggested questions to ask patients include, “Do you think I understand your concerns?” and “Is there anything I can do to help you become more willing to take your medicines?”
        </p>
        <p>
         Some situations demand that clinicians act without patient approval (eg, involuntary admission and court-ordered treatment) [
         <a href="#rid50">
          50
         </a>
         ]. Nevertheless, by listening to patients and attempting to address their concerns, patients may feel that their point of view matters.
        </p>
        <p class="headingAnchor" id="H125287">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple methods are available to monitor adherence and using more than one may provide more accurate estimates. Adherence is typically monitored through patient interviews, and less often by interviewing family members and reviewing medical records [
         <a href="#rid26">
          26
         </a>
         ]. Clinicians should ask patients about adherence behavior and attitudes in a nonjudgmental manner. One approach is to begin by stating, “It can be difficult to always take your medication,” and then asking, “Have you had any problems with that?” or “Do you think you might have problems?” Asking about problems with adherence is thought to be more useful than simply asking whether patients are taking their medications. Additional useful questions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What time of day do you take your medications?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Where do you store your medications?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How do you remember to take your medications? Does someone help or remind you?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How do feel about taking your medications?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are the medicines helpful?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What do you dislike about taking the medicines?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do the medicines cause side effects?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do you plan to continue taking your medications?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have you ever skipped taking your medications on purpose?
        </p>
        <p>
        </p>
        <p>
         For patients who acknowledge poor adherence, follow-up questions should explore the reasons (eg, “What gets in the way of taking your medications?” or “Did you feel better when you stopped the medicines?”). Clinicians often ascribe noncompliance to incorrect reasons [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Monitoring serum concentrations, which is required for some medications (eg,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ) to achieve therapeutic levels and avoid toxicity, can also indicate the level of adherence. Serum concentrations of other drugs that do not have established therapeutic levels can nevertheless be assayed to check whether patients are taking any of their drugs.
        </p>
        <p>
         The frequency of monitoring adherence depends upon the patient’s clinical status and presumed level of adherence [
         <a href="#rid26">
          26
         </a>
         ]. A lack of response to treatment, noticeable change in symptoms, or missed appointments should prompt an assessment. In addition, well-known patients who are thought to be fully compliant are generally assessed every one to three months. Relatively new patients who regularly adhere to treatment are monitored monthly. Patients whose adherence is problematic or who are not responding to treatment are monitored weekly.
        </p>
        <p>
         Other methods to monitor adherence include validated self-administered scales (eg, the Medication Adherence Rating Scale, which is in the public domain) and clinician administered scales (eg, the Brief Adherence Rating Scale, which is in the public domain), counting pills in the bottle, checking pharmacy records for missed refills, and electronically monitoring pill bottle caps to detect each time the bottle is opened [
         <a href="#rid26">
          26,60,61
         </a>
         ]. However, these methods are not standard clinical practice and are generally limited to research settings.
        </p>
        <p>
         All methods used to monitor adherence are potentially inaccurate [
         <a href="#rid6">
          6
         </a>
         ]. Patient self-report and clinician rating are the most common means of assessing adherence and both tend to underestimate noncompliance [
         <a href="#rid6">
          6,26,62
         </a>
         ]. Even electronic monitoring, which is regarded as the gold standard, can be compromised by patients removing more than one dose at a time, failing to replace the cap before the next dose, or opening the bottle solely to check how much medication is left.
        </p>
        <p class="headingAnchor" id="H432432394">
         <span class="h3">
          Customized pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest clinicians take a flexible approach and accommodate patient preferences to the extent that they are feasible [
         <a href="#rid7">
          7
         </a>
         ]. One option when selecting a medication is to provide a list of possibilities and allow patients to make the final choice [
         <a href="#rid50">
          50
         </a>
         ]. In addition, patients are more likely to adhere to treatment if they choose the drug formulation (eg, extended release pills, sublingual tablets, transdermal patches, and liquid), frequency of doses, and timing of administration. In addition, some patients with bipolar disorder want to try a drug regimen that differs from their current regimen [
         <a href="#rid63">
          63
         </a>
         ]. Many patients prefer simpler regimens with fewer drugs that are prescribed less often per day [
         <a href="#rid7">
          7
         </a>
         ]. Studies in bipolar disorder as well as multiple reviews of different illnesses indicate that adherence is superior with medications administered once per day compared with more frequent doses [
         <a href="#rid53">
          53,64,65
         </a>
         ].
        </p>
        <p>
         Some patients avoid medications because they are not “natural.” It may be possible to accommodate this belief by suggesting
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , which is found in nature as a salt [
         <a href="#rid66">
          66
         </a>
         ]. In addition, lithium can be administered once daily. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'
         </a>
         .)
        </p>
        <p>
         One option for maintenance treatment of bipolar disorder is a long-acting injectable antipsychotic (eg,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ), but this option is used infrequently because many patients dislike injections [
         <a href="#rid27">
          27
         </a>
         ]. In addition, long-acting injectable antipsychotics do not necessarily improve adherence. (See
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H432432759">
         <span class="h3">
          Access to clinicians
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar patients who perceive that their clinicians are available report better medication adherence [
         <a href="#rid7">
          7
         </a>
         ]. Thus, clinicians are encouraged to optimize their availability (eg, open the clinic during evening hours) [
         <a href="#rid53">
          53
         </a>
         ]. We suggest informing patients to consult the clinician if problems arise and before discontinuing medications. In addition, ask patients [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is it difficult to get an appointment when you feel you need to see me?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When you call the office with a question about your illness or medications, do you get an answer? Do you have to wait long?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H86903017">
         <span class="h3">
          Negative expectations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Negative expectations about the effects of medications can diminish therapeutic efficacy and amplify unwanted side effects; adverse outcomes that are induced by psychological factors are referred to as nocebo effects [
         <a href="#rid67">
          67
         </a>
         ]. As an example, a study found that negative expectations regarding treatment were related to bipolar patients discontinuing
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Clinicians can manage negative expectations about medications by [
         <a href="#rid67">
          67
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Explaining the desired therapeutic effects (eg, “
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         reduces the risk of relapse by almost 50 percent”) when discussing potential side effects. It may be helpful to elicit benefits that are meaningful and specific to the patient; doing so communicates understanding and acceptance. Explain that it may take several weeks for the benefits to manifest.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ensuring that patients understand that many side effects are transient and benign. In addition, side effects can be reframed as an indication that the medication is working.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discussing techniques for coping with side effects other than stopping the drug.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H125293">
         <span class="h2">
          Specific interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific interventions for maintaining or improving adherence to pharmacotherapy for bipolar disorder typically consist of psychosocial interventions that include an element that addresses adherence [
         <a href="#rid1">
          1,2
         </a>
         ]. In nearly all psychosocial interventions that support adherence, psychoeducation constitutes either a major component of the intervention or the entire intervention [
         <a href="#rid7">
          7,60
         </a>
         ]. However, many interventions are complex and require substantial resources [
         <a href="#rid60">
          60
         </a>
         ], and adherence-enhancement interventions are more likely to be adopted if they are readily available, affordable, and practical [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Evidence supporting the use of interventions for medication adherence in bipolar disorder includes a meta-analysis of 18 randomized trials (n &gt;1300 patients) that compared specific interventions with control conditions [
         <a href="#rid60">
          60
         </a>
         ]. Active treatment included psychoeducation, cognitive-behavioral therapy, or family therapy; control conditions included usual care. The median number of treatment sessions was 17 and the median length of follow-up after the last treatment session was six months. Adherence was two times more likely with specific interventions than control conditions (odds ratio 2.3, 95% CI 1.5-3.6). However, heterogeneity across studies was moderate.
        </p>
        <p>
         Separate topics discuss the adjunctive psychotherapies that are used for maintenance treatment of bipolar disorder, as well as choosing a specific psychotherapy for maintenance treatment. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Choosing adjunctive psychotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H125299">
         <span class="h3">
          Group psychoeducation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychoeducation is often considered the treatment of choice for improving adherence [
         <a href="#rid69">
          69
         </a>
         ]. Multiple randomized trials indicate that group psychoeducation can enhance medication adherence in bipolar disorder [
         <a href="#rid70">
          70
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 21-week randomized trial compared group psychoeducation with a nonspecific support group as add-on treatment in 120 euthymic patients who were receiving pharmacotherapy; both groups met weekly for 90 minutes, and patients were followed for up to two years after treatment [
         <a href="#rid71">
          71
         </a>
         ].
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         serum concentrations were greater in the subgroup of patients who received psychoeducation (n = 49) than the subgroup that received nonspecific support (n = 44) (0.8 versus 0.7 mEq/L [0.8 versus 0.7 mmol/L]) [
         <a href="#rid72">
          72
         </a>
         ]. This benefit was consistent with the finding in the total sample that prevention of relapse was superior with psychoeducation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week randomized trial compared group psychoeducation (weekly sessions, each lasting 90 to 120 minutes) with a control condition (weekly group sessions, each lasting 5 to 10 minutes) as add-on treatment in 71 euthymic patients who were receiving pharmacotherapy [
         <a href="#rid73">
          73
         </a>
         ]. Approximately 40 percent of patients in each group were adherent at study enrollment. At the end of treatment, the number of patients who were adherent was greater in the group who received psychoeducation, compared with the control group (80 versus 31 percent of patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week randomized trial compared group psychoeducation (a 12-minute videotaped lecture and written information about the use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ) plus a home visit with a waiting-list control group in 60 patients receiving lithium [
         <a href="#rid74">
          74
         </a>
         ]. Improvement of adherence (reduced number of missed doses) was greater in patients who received active treatment.
        </p>
        <p>
        </p>
        <p>
         In addition, a 12-week randomized trial compared group psychoeducation (weekly sessions lasting 90 minutes) plus pharmacotherapy with pharmacotherapy alone in 53 remitted patients; each patient assigned to group psychoeducation attended the sessions with a companion (eg, spouse) [
         <a href="#rid75">
          75
         </a>
         ]. Adherence during follow-up lasting 48 weeks was superior with active treatment.
        </p>
        <p>
         Another randomized trial compared group psychoeducation plus pharmacotherapy with individual CBT plus pharmacotherapy in 204 remitted bipolar patients [
         <a href="#rid76">
          76
         </a>
         ]. Medication adherence was excellent in both treatment arms. However, group psychoeducation was more efficient. Psychoeducation was administered in six sessions in a group format (minimum of four patients per group), with each session lasting 90 minutes. By contrast, CBT was administered individually (one therapist and one patient) over 20 sessions, with each session lasting 50 minutes. Also, administering group psychoeducation requires less training and skill than is needed for CBT [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Patients who complete psychoeducation may perhaps benefit from a serious game, which involves a computer application that provides a fun means of learning and accomplishing a goal. In a small, open-label, one-month randomized trial in 41 euthymic patients with bipolar disorder, medication adherence at baseline was less in patients who received a serious game rather than usual care [
         <a href="#rid78">
          78
         </a>
         ]. Subsequently, at the one- and four-month assessments, adherence in the two groups was comparable.
        </p>
        <p>
         The administration, content, and efficacy of adjunctive group psychoeducation for the maintenance treatment of bipolar disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86903148">
         <span class="h3">
          Cognitive-behavioral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         CBT can help bipolar patients adhere with pharmacotherapy. A meta-analysis of randomized trials (number of trials and study patients was not reported) compared CBT with a control condition and found a significant, clinically moderate effect favoring CBT [
         <a href="#rid79">
          79
         </a>
         ]. Additional information about the use of CBT for the maintenance treatment of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Cognitive-behavioral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H179359368">
         <span class="h3">
          Family therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enlisting family members and significant others to support the use of pharmacotherapy can enhance adherence. Family members can promote optimism about treatment, assist with adherence, and provide information about barriers to adherence [
         <a href="#rid55">
          55,56
         </a>
         ]. Family psychoeducation is indicated if family members are advising patients to not take their medications [
         <a href="#rid33">
          33
         </a>
         ]. Evidence for the efficacy of adjunctive family therapy includes randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A nine-month randomized trial (n = 101 remitted bipolar patients) compared family therapy (21 one-hour sessions) plus pharmacotherapy with pharmacotherapy augmented by two psychoeducation sessions, each lasting one hour [
         <a href="#rid80">
          80
         </a>
         ]. Family therapy and psychoeducation sessions were conducted in patients’ homes, and patients were followed for up to two years. Medication adherence was better in patients who received family therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An 11-month randomized trial that compared marital therapy focused upon psychoeducation plus pharmacotherapy with pharmacotherapy alone in 33 bipolar patients who completed the study [
         <a href="#rid81">
          81
         </a>
         ]. Each couple met with their therapist for up to 25 sessions. Adherence was greater in the group that received adjunctive marital therapy.
        </p>
        <p>
        </p>
        <p>
         Additional information about the use of family therapy for the maintenance treatment of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Family therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3295385020">
         <span class="h3">
          Integrative therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         This adjunctive treatment integrates psychoeducation, family therapy, cognitive remediation, mindfulness training, and physical health care for patients with bipolar disorder [
         <a href="#rid82">
          82,83
         </a>
         ]. Treatment typically occurs in a group format but can be implemented individually. A 12-week randomized trial compared usual care alone with usual care plus integrative therapy (weekly group sessions lasting 90 minutes) in 94 patients who were either euthymic or had subthreshold bipolar symptoms [
         <a href="#rid83">
          83
         </a>
         ]. Improvement of psychosocial functioning and subsyndromal depression was greater with add-on integrative therapy; however, attrition was substantial.
        </p>
        <p class="headingAnchor" id="H86903216">
         <span class="h3">
          Other options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other interventions that may possibly reinforce adherence include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Motivational interviewing
         </strong>
         – Motivational interviewing is used to enhance adherence in many illnesses, including bipolar disorder [
         <a href="#rid7">
          7
         </a>
         ]. A three-week prospective observational study of motivational interviewing (one individual meeting and two follow-up telephone sessions) in 14 bipolar patients found that the therapy improved medication adherence [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The basic aim of motivational interviewing is to help patients acknowledge that adherence with pharmacotherapy is problematic, make a commitment to change their behavior, and take action to change. The general approach is to initially ask questions and to give advice later. Other elements include expressing empathy (eg, “I know this is hard”), focusing upon collaboration, and avoiding arguments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment sessions explore the:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical, psychological, and psychosocial effects of bipolar disorder and nonadherence upon the patient’s life
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pros and cons of nonadherence
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Value and meaning of nonadherence in the patient’s life
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient’s goals in life
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Motivations for changing medication behavior (potential benefits)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ambivalence about and barriers to changing medication behaviors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Discrepancy between the patient’s current state of functioning and desired future state
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Customized adherence enhancement
         </strong>
         – Customized adherence enhancement initially identifies bipolar patients who poorly adhere to medications and the reasons for noncompliance, and then administers up to four intervention modules based upon those reasons [
         <a href="#rid85">
          85,86
         </a>
         ]. The modules are psychoeducation about bipolar disorder, motivational interviewing for substance abuse, communicating with clinicians about treatment planning, and medication routines. Treatment is administered over four weekly, individual, 60-minute sessions with two follow-up telephone sessions. A six-month prospective observational study in 43 patients with poor adherence found that customized adherence enhancement was associated with improved adherence, symptoms, and functioning [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Telephone- and internet-based interventions
         </strong>
         – Telephone- and internet-based interventions may improve treatment adherence in bipolar disorder [
         <a href="#rid88">
          88
         </a>
         ]. As an example, a six-month randomized trial compared pharmacotherapy plus semimonthly telephone calls with pharmacotherapy alone in patients discharged from the hospital (n = 120, 20 percent with bipolar disorder) [
         <a href="#rid89">
          89
         </a>
         ]. After adjusting for potential confounding factors (eg, age, diagnosis, and number of medications), the analyses found that medication adherence was greater in patients who received adjunctive telephone calls (odds ratio 7, 95% CI 2-23). In addition, pooled data from two randomized trials found that smartphone-based monitoring of adherence to medication is valid compared with a validated paper-based adherence questionnaire [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1563361215">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349952278">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder is a mood disorder that is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Bipolar disorder'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adherence to pharmacotherapy encompasses taking medication as prescribed with regard to dose, frequency, and timing. Common but arbitrary cutoffs for good adherence are taking at least 70 or 80 percent of prescribed doses. (See
         <a class="local">
          'Medication adherence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many studies have found that poor adherence with pharmacotherapy occurs in roughly 50 percent of bipolar patients. Long-acting injectable antipsychotics do not necessarily improve adherence. Factors that are associated with nonadherence include comorbid substance use disorder, side effects, and patient beliefs. (See
         <a class="local">
          'Epidemiology of nonadherence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Techniques that can improve medication adherence include the following: help patients accept the diagnosis; discuss with patients their expectations of benefits and adverse effects, how the clinician will monitor the use and benefit of medications, the clinician’s availability for questions about treatment, and plans for dose titrations; elicit benefits that are important to the patient; provide written instructions for taking prescribed medications; suggest using pill boxes and cues as a reminder to take medications; ask about the patient’s ability to follow the regimen and address barriers to adherence; discuss the need to maintain pharmacotherapy despite feeling better; identify poor adherence; and reinforce desirable behavior. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aspects of treatment relevant to medication adherence include developing a therapeutic alliance, monitoring adherence, customizing pharmacotherapy, providing access to the clinician, and managing negative expectations. (See
         <a class="local">
          'Therapeutic alliance'
         </a>
         above and
         <a class="local">
          'Monitoring'
         </a>
         above and
         <a class="local">
          'Customized pharmacotherapy'
         </a>
         above and
         <a class="local">
          'Access to clinicians'
         </a>
         above and
         <a class="local">
          'Negative expectations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Randomized trials indicate that adherence to pharmacotherapy for bipolar disorder can be enhanced with group psychoeducation, cognitive-behavioral therapy, family therapy, and online mental health resources. (See
         <a class="local">
          'Specific interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ 2012; 345:e8508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. JAMA 2013; 310:2611.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busby KK, Sajatovic M. REVIEW: Patient, treatment, and systems-level factors in bipolar disorder nonadherence: A summary of the literature. CNS Neurosci Ther 2010; 16:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin JB, Krivenko A, Howland M, et al. Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review. CNS Drugs 2016; 30:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arvilommi P, Suominen K, Mantere O, et al. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study. J Affect Disord 2014; 155:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin JB, Aebi ME, Tatsuoka C, et al. Adherence to Psychotropic and Nonpsychotropic Medication Among Patients With Bipolar Disorder and General Medical Conditions. Psychiatr Serv 2016; 67:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang K, Korn J, Muser E, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ 2011; 14:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleck DE, Keck PE Jr, Corey KB, Strakowski SM. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry 2005; 66:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou R, Cleak V, Peveler R. Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study. Eur Psychiatry 2010; 25:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colom F, Vieta E, Martínez-Arán A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000; 61:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strakowski SM, Keck PE Jr, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998; 55:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997; 33:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morselli PL, Elgie R, GAMIAN-Europe. GAMIAN-Europe/BEAM survey I--global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord 2003; 5:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeber JE, Copeland LA, Good CB, et al. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. J Affect Disord 2008; 107:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009; 70:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry 2010; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig TJ, Grossman S, Mojtabai R, et al. Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features. Bipolar Disord 2004; 6:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon E, Chang JS, Kim MY, et al. Dropout rate and associated factors in patients with bipolar disorders. J Affect Disord 2012; 141:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagalman E, Yu-Isenberg KS, Durden E, et al. Indirect costs associated with nonadherence to treatment for bipolar disorder. J Occup Environ Med 2010; 52:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sylvia LG, Reilly-Harrington NA, Leon AC, et al. Medication adherence in a comparative effectiveness trial for bipolar disorder. Acta Psychiatr Scand 2014; 129:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract 2010; 16:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010; 16:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol 2010; 25:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Bauer MS, Kilbourne AM, et al. Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv 2006; 57:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol 2008; 23:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong J, Reed C, Novick D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 2011; 190:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006; 8:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Levin J, Fuentes-Casiano E, et al. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry 2011; 52:280.
          </a>
         </li>
         <li class="breakAll">
          Colom F, Berk L. Psychoeducation as a core element of psychological approaches for bipolar disorders. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.412.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 2013; 127:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother 2013; 13:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Pinto A, Reed C, Novick D, et al. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 2010; 43:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devulapalli KK, Ignacio RV, Weiden P, et al. Why do persons with bipolar disorder stop their medication? Psychopharmacol Bull 2010; 43:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope M, Scott J. Do clinicians understand why individuals stop taking lithium? J Affect Disord 2003; 74:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianfrancesco FD, Sajatovic M, Tafesse E, Wang RH. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder. Ann Clin Psychiatry 2009; 21:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry 2009; 50:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuentes I, Rizo-Méndez A, Jarne-Esparcia A. Low compliance to pharmacological treatment is linked to cognitive impairment in euthymic phase of bipolar disorder. J Affect Disord 2016; 195:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murru A, Pacchiarotti I, Amann BL, et al. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 2013; 151:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belzeaux R, Boyer L, Mazzola-Pomietto P, et al. Adherence to medication is associated with non-planning impulsivity in euthymic bipolar disorder patients. J Affect Disord 2015; 184:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry 2009; 8:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009; 66:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 2006; 19:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez-Rojas L, Jurado D, Martínez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010; 127:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.
          </a>
         </li>
         <li class="breakAll">
          Scott J, Tacchi MJ. Treatment adherence in bipolar disorder. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.275.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005; 7 Suppl 5:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://www.psychiatry.org/practice/clinical-practice-guidelines (Accessed on July 09, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss JL, Johnson SL. Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms. Psychiatry Res 2006; 145:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sylvia LG, Hay A, Ostacher MJ, et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol 2013; 33:343.
          </a>
         </li>
         <li class="breakAll">
          Horvath AO, Greenberg LS. Working Alliance Inventory. In: Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.187.
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald L, Chapman S, Syrett M, et al. Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. J Affect Disord 2016; 194:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culig J, Leppée M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. Coll Antropol 2014; 38:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson JJ, Tunceli O, Gu T, et al. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims. Int J Clin Pract 2012; 66:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blixen C, Levin JB, Cassidy KA, et al. Coping strategies used by poorly adherent patients for self-managing bipolar disorder. Patient Prefer Adherence 2016; 10:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996; 57:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013; 9:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makela EH, Griffith RK. Enhancing treatment of bipolar disorder using the patient's belief system. Ann Pharmacother 2003; 37:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bingel U, Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014; 312:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleindienst N, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J Clin Psychiatry 2004; 65:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord 2013; 149:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javadpour A, Hedayati A, Dehbozorgi GR, Azizi A. The impact of a simple individual psycho-education program on quality of life, rate of relapse and medication adherence in bipolar disorder patients. Asian J Psychiatr 2013; 6:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colom F, Vieta E, Sánchez-Moreno J, et al. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 2005; 7 Suppl 5:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eker F, Harkın S. Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder. J Affect Disord 2012; 138:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey NS, Peet M. Lithium maintenance: 2. Effects of personality and attitude on health information acquisition and compliance. Br J Psychiatry 1991; 158:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Souza R, Piskulic D, Sundram S. A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial. J Affect Disord 2010; 120:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh SV, Zaretsky A, Beaulieu S, et al. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. J Clin Psychiatry 2012; 73:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colom F. Keeping therapies simple: psychoeducation in the prevention of relapse in affective disorders. Br J Psychiatry 2011; 198:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurin KD, Girod C, Consolini JL, et al. Use of a serious game to strengthen medication adherence in euthymic patients with bipolar disorder following a psychoeducational programme: A randomized controlled trial. J Affect Disord 2020; 262:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szentagotai A, David D. The efficacy of cognitive-behavioral therapy in bipolar disorder: a quantitative meta-analysis. J Clin Psychiatry 2010; 71:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miklowitz DJ, George EL, Richards JA, et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarkin JF, Carpenter D, Hull J, et al. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998; 49:531.
          </a>
         </li>
         <li class="breakAll">
          Reinares M, Martinez-Aran A, Vieta E. Psychotherapy for bipolar disorder: An integrative approach, Cambridge University Press, 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valls È, Bonnín CM, Torres I, et al. Efficacy of an integrative approach for bipolar disorder: preliminary results from a randomized controlled trial. Psychol Med 2021; 52:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenzie K, Chang YP. The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder. Perspect Psychiatr Care 2015; 51:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Levin J, Tatsuoka C, et al. Customized adherence enhancement for individuals with bipolar disorder receiving antipsychotic therapy. Psychiatr Serv 2012; 63:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Tatsuoka C, Cassidy KA, et al. A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder. J Clin Psychiatry 2018; 79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajatovic M, Levin J, Tatsuoka C, et al. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder. Bipolar Disord 2012; 14:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenze SJ, Armey MF, Weinstock LM, et al. An Open Trial of a Smartphone-assisted, Adjunctive Intervention to Improve Treatment Adherence in Bipolar Disorder. J Psychiatr Pract 2016; 22:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulze LN, Stentzel U, Leipert J, et al. Improving Medication Adherence With Telemedicine for Adults With Severe Mental Illness. Psychiatr Serv 2019; 70:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faurholt-Jepsen M, Frost M, Christensen EM, et al. Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evid Based Ment Health 2020; 23:2.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 96007 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Treatment of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23271744" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24264605" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ingredients of successful interventions to improve medication adherence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24264605" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Ingredients of successful interventions to improve medication adherence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18237359" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Medication compliance and persistence: terminology and definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21050421" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : REVIEW: Patient, treatment, and systems-level factors in bipolar disorder nonadherence: A summary of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27435356" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262639" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26695494" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adherence to Psychotropic and Nonpsychotropic Medication Among Patients With Bipolar Disorder and General Medical Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16696824" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment adherence with antipsychotic medications in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21370989" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15889954" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Factors associated with medication adherence in African American and white patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20005683" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10982196" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical factors associated with treatment noncompliance in euthymic bipolar patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9435760" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Twelve-month outcome after a first hospitalization for affective psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9133756" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Compliance with maintenance treatment in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12895204" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : GAMIAN-Europe/BEAM survey I--global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17822779" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19497247" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment nonadherence and neurocognitive impairment in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21274363" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15383133" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17535948" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22410504" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dropout rate and associated factors in patients with bipolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20431414" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Indirect costs associated with nonadherence to treatment for bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24117232" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Medication adherence in a comparative effectiveness trial for bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20098229" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20859108" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20041478" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Enhancing medication adherence in patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16399963" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Self-reported medication treatment adherence among veterans with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18058849" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Factors associated with treatment nonadherence among US bipolar disorder patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21571375" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17042834" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21497222" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21497222" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22900964" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Predictors of medication adherence in patients with schizophrenia and bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23898852" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mood disorders medications: predictors of nonadherence - review of the current literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20842617" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Assessment of medication adherence in a cohort of patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21150842" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Why do persons with bipolar disorder stop their medication?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12738048" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Do clinicians understand why individuals stop taking lithium?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19239828" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19216885" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26897294" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Low compliance to pharmacological treatment is linked to cognitive impairment in euthymic phase of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24099884" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment adherence in bipolar I and schizoaffective disorder, bipolar type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26070047" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adherence to medication is associated with non-planning impulsivity in euthymic bipolar disorder patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19226463" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19202045" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17017312" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The effect of medication adherence on health care utilization in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20576292" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790458" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A meta-analysis of the association between adherence to drug therapy and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790458" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A meta-analysis of the association between adherence to drug therapy and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19686636" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225557" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Identifying and improving non-adherence in bipolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Adherence to medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541066" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A collaborative approach to the treatment alliance in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17079023" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609394" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609394" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26851552" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24851597" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : From Morisky to Hill-bone; self-reports scales for measuring adherence to medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22574724" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27524888" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Coping strategies used by poorly adherent patients for self-managing bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8666570" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Factors associated with pharmacologic noncompliance in patients with mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23355782" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12659613" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Enhancing treatment of bipolar disorder using the patient's belief system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25003609" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Avoiding nocebo effects to optimize treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15291686" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23489403" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Determinants of adherence to treatment in bipolar disorder: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23642977" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The impact of a simple individual psycho-education program on quality of life, rate of relapse and medication adherence in bipolar disorder patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12695318" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225558" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316565" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2012911" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Lithium maintenance: 2. Effects of personality and attitude on health information acquisition and compliance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19428117" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22795205" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21525516" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Keeping therapies simple: psychoeducation in the prevention of relapse in affective disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31668996" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Use of a serious game to strengthen medication adherence in euthymic patients with bipolar disorder following a psychoeducational programme: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19852904" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The efficacy of cognitive-behavioral therapy in bipolar disorder: a quantitative meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963672" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9550248" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9550248" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33858527" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of an integrative approach for bipolar disorder: preliminary results from a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24433493" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22302337" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Customized adherence enhancement for individuals with bipolar disorder receiving antipsychotic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30256551" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22548902" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824786" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : An Open Trial of a Smartphone-assisted, Adjunctive Intervention to Improve Treatment Adherence in Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30651059" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Improving Medication Adherence With Telemedicine for Adults With Severe Mental Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32046986" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
